11月26日宣布的Sarepta与Arrowhead Pharmaceuticals (NASDAQ:ARWR)的最新合作关系重新引发了投资者的浓厚兴趣。消息公布后，Sarepta股价在收盘时上涨了14%。这笔交易被视为一个积极举措，解决了人们对近期催化剂和长期可持续增长的担忧。

Sarepta Therapeutics (SRPT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Kostas ...

H.C. Wainwright lowered the firm’s price target on Sarepta (SRPT) to $75 from $80 and keeps a Sell rating on the shares. Sarepta’s deal to ...

On Wednesday, Sarepta Therapeutics Inc (SRPT) stock saw a modest uptick, ending the day at $137.94 which represents a slight increase of $7.44 or 5.70% from the prior close of $130.5. The stock opened ...

Analysts at HC Wainwright issued their FY2024 EPS estimates for Sarepta Therapeutics in a research note issued to investors ...

Shares of Sarepta Therapeutics SRPT have soared 43% year to date, significantly outperforming the industry’s 6.9% decline.

Check the time stamp on this data. Updated AI-Generated Signals for Sarepta Therapeutics Inc. (SRPT) available here: SRPT.

We recently published a list of 12 High Growth Large Cap Stocks to Buy Now. In this article, we are going to take a look at ...

周二，美银美林维持对Sarepta Therapeutics (NASDAQ:SRPT)的积极立场，重申"优于大市"评级，目标价为$200.00。该公司的乐观情绪源于Sarepta最近与Arrowhead达成的全球许可和合作协议，预计这将显著增强Sarepta的产品管线。

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Sarepta in-licenses rights to four clinical-stage and three preclinical-stage programs targeting muscle, central nervous system and rare pulmonary disorders.